Therapeutics Cell Manufacturing Facility

 The Therapeutics Cell Manufacturing facility specializes in translating laboratory discoveries into real-world treatments. It is one of only a very few pediatric-dedicated facilities in the U.S. that follows the Good Manufacturing Practices (GMP) for manufacturing therapeutic cell products for early phase IND clinical trials. The facility has already manufactured products for use in 14 phase 1 and phase 2 clinical trials.

Following a recent relocation from Seattle Children’s Olive Lab to the organization’s newest research facility, Building Cure, the Therapeutics Cell Manufacturing facility's state-of-the-art amenities include an 11,000-square-foot clean room space, a quality control lab and a process development lab (more than doubling Seattle Children’s Therapeutics’ previous 4,700 square feet of GMP space). The Therapeutics Cell Manufacturing facility's expert team helps researchers navigate every step in the process of adapting research laboratory methods to a manufacturing environment, including required release testing, final product characterization and regulatory support. The team also has the capability to integrate with a third party.

Learn about how the work of the Therapeutics Cell Manufacturing facility team contributed to the FDA Approval of a chimeric antigen receptor (CAR) T-cell immunotherapy treatment for adults with relapsed or refractory large B-cell lymphoma.

How to Get Started

We recommend that researchers who anticipate manufacturing clinical-grade therapies start working with the Therapeutics Cell Manufacturing facility as early as possible for assistance in process development, establishing timelines and milestones, and budget development for grant proposals.

For more information, please fill out the fields below and click “Submit.”

Our Services

  • Assistance developing budgets for grant proposals
  • Pre-clinical assistance, analytical assay and manufacturing process development, product scale-up and clinical grade reagent/materials sourcing
  • Consultation for regulatory submissions (IND, IRB, NIH, IBC)
  • Development of standard operating procedures for manufacturing
  • GMP-compliant documentation
  • Full-service manufacturing by highly-trained manufacturing staff
  • Quality control/in-house testing of manufactured products
  • Coordination and facilitation of offsite testing
  • Product transport to clinical sites
  • Long-term manufacturing archiving
  • Quality assurance oversight to ensure clinical product safety and regulatory compliance

In addition to quality control (QC) testing performed in support of clinical manufacture, Therapeutics Cell Manufacturing facility QC services are available to Seattle Children's Research Institute researchers. These include the following:

  • Mycoplasma testing by PCR
  • Endotoxin testing by Endosafe PTS
  • Bioplex assay